latest update:
[TrialBase DB]

trial summary · NCT05487911

Cortical rTMS as a Treatment for Depression

Trial record from the TrialBase DB dataset, status RECRUITING, condition Major Depressive Disorder, sponsored by Baylor College of Medicine. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT05487911phase —enrollment 50start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Depression is a leading cause of disability worldwide with a 19% lifetime prevalence in the United States. Dysfunctional reward processing is one of the core features of depression. Common treatments of depression include psychological therapies (e.g., cognitive behavioral therapy), medication (e.g., bupropion, sertraline) and psychological therapies and medication combined, but they may not address the function of the reward circuit in depression. These treatments often o not improve depressive symptoms in patients with depression who are classified as having treatment-resistant depression, and they may be unlikely to respond to further medication trials. Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation that enables us to selectively excite or inhibit neural activity. Multiple TMS pulses given consecutively are known as repetitive TMS (rTMS), and the primary clinical location for applying rTMS is the left dorsolateral prefrontal cortex (DLPFC) for treatment of depressive symptoms. Many of these studies have shown that rTMS to the DLPFC may result in decreased depressive symptoms, but is only partially effective (response and remission rates of 41.2 and 35.3%, respectively). This evidence supports the importance of evaluating the efficacy of rTMS in other brain regions, such as the orbitofrontal cortex (OFC), in the treatment of depressive symptoms rather than in the DLPFC.

Source record: https://clinicaltrials.gov/study/NCT05487911

Facts

registry idNCT05487911
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionMajor Depressive Disorder
sponsorBaylor College of Medicine
sponsor classOTHER
enrollment50
start date2026-11-01
primary completion2028-07-31
completion2028-08-31
results postednot reported

Conditions

  • Major Depressive Disorder
  • Opioid Use Disorder
  • Suicidality

Interventions

  • Repetitive Transcranial Magnetic Stimulation

Countries

  • United States

Intervention types: DEVICE

Work with this record